RNS Number : 3304T
N4 Pharma PLC
24 March 2021

**24 March 2021**

**N4 Pharma plc**

("**N4 Pharma**" or the "**Company**")

## Result of Annual General Meeting

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. The results of the proxy voting for the AGM are set out below.

| Resolution (*Special Resolution) | Total Shares Voted | Shares | | % | |
|---|---|---|---|---|---|
| | | For | Against | For | Against |
| | | | | | |
| **1.** To receive the annual report and audited accounts for the year ended 31 December 2020 | 20,289,075 | 20,222,189 | 66,886 | 99.67 | 0.33 |
| **2.** To re-elect Chris Britten as a Director of the Company | 20,286,756 | 20,153,341 | 133,415 | 99.34 | 0.66 |
| **3.** To re-elect Luke Cairns as a Director of the Company | 20,286,756 | 20,194,827 | 91,929 | 99.55 | 0.45 |
| **4.** To re-elect John Chiplin as a Director of the Company | 20,286,756 | 20,209,370 | 77,386 | 99.62 | 0.38 |

| Resolution (*Special Resolution) | Total Shares Voted | Shares | | % | |
|---|---|---|---|---|---|
| | | For | Against | For | Against |
| **5.** To re-appoint Saffery Champness LLP as auditor to the company and authorise the directors to determine their remuneration | 20,219,901 | 20,134,176 | 85,725 | 99.58 | 0.42 |
| **6.** To authorise the Directors to allot shares | 20,283,475 | 20,101,362 | 182,113 | 99.10 | 0.90 |
| **7***. To disapply pre-emption rights | 20,250,090 | 20,123,051 | 127,039 | 99.37 | 0.63 |

**Enquiries:**


**N4 Pharma plc**

Nigel Theobald, CEO — Via IFC Advisory

Luke Cairns, Executive Director

**SP Angel Corporate Finance LLP** — Tel: +44(0)20 3470 0470

*Nominated Adviser and Joint Broker*

Matthew Johnson/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Rob Rees (Corporate Broking)

**Turner Pope Investments (TPI) Limited** — Tel: +44(0)20 3657 0050

*Joint Broker*

Andy Thacker/Zoe Alexander

**IFC Advisory Ltd** — Tel: +44(0)20 3934 6630

*Financial PR*

Graham Herring

Zach Cohen

**About N4 Pharma**

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBGGDXBSDDGBS